150314-34-4 Usage
Description
DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE, also known as (8Z,11Z,14Z)-N-(2-Hydroxyethyl)-8,11,14-eicosatrienamide, is an endocannabinoid that exhibits significant interactions with the human endocannabinoid system. It possesses the ability to bind to both recombinant human CB1 and CB2 receptors, making it a potent agonist for these receptors. Additionally, it functions as an adenylyl cyclase inhibitor, which further contributes to its diverse range of potential applications.
Uses
Used in Pharmaceutical Applications:
DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE is used as a therapeutic agent for various medical conditions due to its agonistic effects on CB1 and CB2 receptors. Its interaction with these receptors can potentially modulate pain, inflammation, and other immune responses, making it a promising candidate for the treatment of chronic pain, inflammation-related disorders, and neurodegenerative diseases.
Used in Neurological Applications:
In the field of neurology, DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE is used as a neuroprotective agent for its potential to alleviate symptoms associated with neurodegenerative conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. Its agonistic activity on CB1 and CB2 receptors may help in reducing neuroinflammation and promoting neuroprotection.
Used in Pain Management:
DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE is used as an analgesic agent for its ability to modulate pain perception through its interaction with the endocannabinoid system. This makes it a potential candidate for the development of novel pain management therapies, particularly for chronic and intractable pain conditions.
Used in Immunomodulation:
In the field of immunology, DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE is used as an immunomodulatory agent due to its influence on the endocannabinoid system, which plays a crucial role in regulating immune responses. This property can be harnessed for the development of treatments targeting autoimmune diseases and other conditions involving immune system dysregulation.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of DIHOMO-GAMMA-LINOLENYLETHANOLAMIDE, novel drug delivery systems are being developed. These systems, which may include organic and metallic nanoparticles, aim to improve the delivery of the compound to target tissues, thereby increasing its efficacy and reducing potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 150314-34-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,3,1 and 4 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 150314-34:
(8*1)+(7*5)+(6*0)+(5*3)+(4*1)+(3*4)+(2*3)+(1*4)=84
84 % 10 = 4
So 150314-34-4 is a valid CAS Registry Number.
InChI:InChI=1/C22H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,24H,2-5,8,11,14-21H2,1H3,(H,23,25)/b7-6+,10-9+,13-12+
150314-34-4Relevant articles and documents
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo
Kim, In-Hae,Kanayama, Yoshiki,Nishiwaki, Hisashi,Sugahara, Takuya,Nishi, Kosuke
, p. 9576 - 9592 (2019/11/11)
A series of unsaturated fatty acids in fish oil and their corresponding ethanolamide metabolites were explored to find active fish oil components of antiallergic activity in vitro. Ethanolamides of omega-3 fatty acids (α-linolenic acid, EPA, and DHA) were found to possess promising antiallergic activity, whereas free fatty acids and ethanolamides of other fatty acids exhibited no or weak potency. Based on this finding, structure-activity relationships of DHA-ethanolamide (DHEA) derivatives were investigated to yield better fatty acid derivatives with enhanced antiallergic activity in vitro and in vivo. When the ethanolamide moiety of DHEA was replaced by the substituted sulfonamide functionality, highly promising potency was provided in vitro. Compound 59 showed improved antiallergic activity in vivo over DHEA. The results indicate that optimized DHEA derivatives have enhanced antiallergic activity in vitro and in vivo, and the resulting structures will be an important basis for further development of bioavailable derivatives with promising allergy suppressive activity.
